# A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

> **NCT06190639** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** sintilimab

## Key facts

- **NCT ID:** NCT06190639
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190639, "A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06190639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*